Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDENE vs ADALAT CC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It dilates peripheral arterioles, reducing systemic vascular resistance and blood pressure, and also has coronary vasodilatory effects.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
Hypertension (chronic stable angina is not an approved indication in the US; however, it is used off-label for short-term treatment of hypertension in hospitalized patients and for subarachnoid hemorrhage to prevent vasospasm.,Off-label: short-term management of hypertension in hospitalized patients, prevention of cerebral vasospasm after subarachnoid hemorrhage.
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
20-40 mg orally three times daily.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
1.5-2 hours (terminal); prolonged in hepatic impairment (up to 6-8 hours)
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Hepatic metabolism primarily via cytochrome P450 isoenzymes CYP3A4 and CYP2C8, with minor contributions from CYP2D6.
Hepatic metabolism via CYP3A4; nifedipine is converted to inactive metabolites.
Renal: 60% as metabolites, 10% unchanged; Fecal: 35%
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
>95% bound to albumin and alpha-1 acid glycoprotein
92-98% bound primarily to albumin.
0.6-1.2 L/kg (large Vd due to extensive tissue binding)
1.2-1.6 L/kg; clinical meaning: indicates extensive tissue distribution, with higher concentrations in organs such as liver and kidney, and lower in brain due to P-glycoprotein efflux.
Oral: 35-60% (first-pass metabolism; increased with hepatic disease)
65-90% after oral administration; absolute bioavailability of nifedipine in ADALAT CC: approximately 65% due to first-pass metabolism in liver and gut wall.
For GFR < 30 m L/min: initiate at 20 mg orally twice daily.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), start at 30 mg once daily and titrate cautiously.
Child-Pugh class B or C: reduce dose by 50% and titrate slowly.
For mild to moderate hepatic impairment (Child-Pugh A or B), reduce initial dose to 30 mg once daily; for severe impairment (Child-Pugh C), contraindicated or use with extreme caution.
Not established; safety and efficacy not determined.
Safety and efficacy not established; use is not recommended in pediatric patients.
Initiate at 20 mg orally twice daily; titrate cautiously.
Initiate at 30 mg once daily; titrate slowly due to increased risk of hypotension and higher drug exposure. Monitor closely.
No FDA black box warning.
No FDA black box warning.
Hypotension (especially in patients with ventricular dysfunction or those receiving beta-blockers), increased angina (rare, more common with dihydropyridines), peripheral edema, congestive heart failure (use caution in patients with severe left ventricular dysfunction), hepatic impairment (reduce dose), renal impairment (monitor blood pressure), abrupt discontinuation may cause angina exacerbation.
Beta-blocker withdrawal: taper if discontinuing; exacerbation of angina,Heart failure: use caution in patients with severe left ventricular dysfunction,Hepatic impairment: reduce dose,Peripheral edema: may occur; differentiate from worsening heart failure,Monitor blood pressure during initiation and titration
Hypersensitivity to nicardipine or any dihydropyridine, advanced aortic stenosis (may reduce coronary perfusion), second- or third-degree AV block (unless paced), sick sinus syndrome (unless paced), cardiogenic shock, concomitant use with strong CYP3A4 inducers (e.g., rifampin) due to decreased efficacy.
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concurrent use with strong CYP3A4 inducers (e.g., rifampin)
Grapefruit and grapefruit juice increase nicardipine exposure and should be avoided. High-fat meals may reduce absorption; take consistently with or without food. Alcohol may enhance hypotensive effects.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, raising nifedipine levels and risk of toxicity. High-fat meals may increase absorption; take consistently with respect to meals. Avoid alcohol as it may exacerbate hypotension.
Cardene (nicardipine) is classified as FDA Pregnancy Category C. In animal studies, nicardipine was associated with embryotoxicity, fetotoxicity, and teratogenicity at high doses. There are no adequate and well-controlled studies in pregnant women. Use in the first trimester should be avoided if possible; in the second and third trimesters, potential benefits must outweigh risks, particularly due to possible maternal hypotension and fetal hypoxia.
Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotoxicity, fetotoxicity, and teratogenicity (e.g., digital anomalies, cleft palate) at doses several times the maximum recommended human dose. In humans, data are limited but there is no clear evidence of a significant increase in major congenital malformations. First trimester exposure is not strongly associated with major defects; however, some studies suggest a possible small increase in oral clefts. Second and third trimester use may cause maternal hypotension and subsequent fetal distress (e.g., reduced uteroplacental perfusion). Use near term may theoretically inhibit labor, but nifedipine is used as a tocolytic for preterm labor. Overall, the risk is considered low; however, fetal monitoring is recommended if used in pregnancy. FDA Pregnancy Category C (prior to 2015 categorization).
Nicardipine is excreted in human breast milk. The M/P ratio is approximately 0.7. Limited data suggest that concentrations in breast milk are low relative to therapeutic doses, but the effects on the nursing infant are unknown. Caution is advised.
Nifedipine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.56 to 1.0 based on limited data. The estimated daily infant dose via milk is less than 5% of the maternal weight-adjusted dose, which is considered clinically insignificant. No adverse effects have been reported in breastfed infants. However, caution is advised, especially with high maternal doses or prolonged use. The American Academy of Pediatrics considers nifedipine compatible with breastfeeding.
Pregnancy may alter the pharmacokinetics of nicardipine due to increased plasma volume and altered hepatic metabolism. However, specific dose adjustment recommendations are not established. In hypertensive emergencies, intravenous nicardipine is often used at standard doses with careful titration to avoid maternal hypotension. Oral doses may require titration based on response, starting at 20 mg three times daily.
Pregnancy may alter the pharmacokinetics of nifedipine due to increased plasma volume and altered hepatic metabolism. However, specific dosing adjustments for Adalat CC in pregnancy are not well established. In clinical practice, dosing for hypertension in pregnancy (e.g., preeclampsia) often uses immediate-release nifedipine, not extended-release. For Adalat CC, the same dosing as in non-pregnant adults (30-90 mg once daily) is typically used, but titration should be cautious to avoid maternal hypotension. No formal dose adjustment is recommended, but careful monitoring and individualized titration are advised.
CARDENE (nicardipine) is a dihydropyridine calcium channel blocker used intravenously for acute hypertension. Onset is rapid (1-2 minutes), making it ideal for hypertensive emergencies. It is metabolized hepatically; reduce dose in hepatic impairment. Does not cause reflex tachycardia as prominently as other dihydropyridines. Contraindicated in advanced aortic stenosis. Can be used for hypertension during pregnancy but with caution.
Adalat CC (nifedipine extended-release) is a dihydropyridine calcium channel blocker used primarily for hypertension. Avoid in patients with unstable angina or within 4 weeks of myocardial infarction due to reflex tachycardia risk. May cause peripheral edema, especially in higher doses; consider adding an ACE inhibitor if edema is problematic. CYP3A4 inhibitors (e.g., grapefruit juice, macrolides, azole antifungals) significantly increase nifedipine levels; avoid coadministration. Tablet shell may appear intact in stool; this is normal.
Take exactly as prescribed; do not stop abruptly.,May cause dizziness or lightheadedness; avoid driving until you know how it affects you.,Avoid grapefruit and grapefruit juice as they may increase drug levels.,Report irregular heartbeat, shortness of breath, or swelling of the ankles or feet.,Keep all appointments for blood pressure monitoring.
Swallow the tablet whole; do not crush or chew.,Do not consume grapefruit or grapefruit juice while taking this medication.,May cause dizziness or lightheadedness; avoid driving if affected.,Notify your doctor if you experience rapid heartbeat, swelling in the ankles or feet, or prolonged erections.,Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDENE vs ADALAT CC, answered by our medical review team.
CARDENE is a Calcium Channel Blocker that works by Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It dilates peripheral arterioles, reducing systemic vascular resistance and blood pressure, and also has coronary vasodilatory effects.. ADALAT CC is a Calcium Channel Blocker that works by Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDENE and ADALAT CC depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDENE is: 20-40 mg orally three times daily.. The standard adult dose of ADALAT CC is: 30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDENE and ADALAT CC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDENE is classified as Category C. Cardene (nicardipine) is classified as FDA Pregnancy Category C. In animal studies, nicardipine was associated with embryotoxicity, fetotoxicity, and teratogenicity at high doses. . ADALAT CC is classified as Category C. Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotox. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.